Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns
The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.